Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Improved remission rates with the IL-6R inhibitor tocilizumab (TCZ) in patients with active rheumatoid arthritis despite DMARD therapy: The toward study Genovese, M. C., Mckay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., Laughton, J., Eves, D., Gomez-Reino, J. J. OXFORD UNIV PRESS. 2008: II50
View details for Web of Science ID 000254680900169